CLOT Conversations – Détails, épisodes et analyse
Détails du podcast
Informations techniques et générales issues du flux RSS du podcast.
CLOT Conversations
Thrombosis Canada
Fréquence : 1 épisode/28j. Total Éps: 52
Unlock the latest breakthroughs in thrombosis diagnosis and management with CLOT Conversations - the must-listen podcast for healthcare professionals. Join hosts Dr Jameel Abdulrehman, a Hematologist with specialization in Thrombosis and Hemostasis at the University Health Network in Toronto, and David Airdrie, the Executive Director of Thrombosis Canada, as they delve into new research and explore the evolving field of thrombosis in 15 to 30 minute easily digestible episodes. Learn from the experts and stay ahead of the curve with Thrombosis Canada, the organization dedicated to promoting excellent patient care and improved outcomes for patients with thrombosis. Access our vast resources, tools, and programs at https://thrombosiscanada.ca and stay informed with CLOT Conversations - your go-to source for all things thrombosis.
Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Apple Podcasts
Aucun classement récent disponible
Spotify
Aucun classement récent disponible
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
See all- https://twitter.com/ParpiaSameer
2 partages
Qualité et score du flux RSS
Évaluation technique de la qualité et de la structure du flux RSS.
See allScore global : 79%
Historique des publications
Répartition mensuelle des publications d'épisodes au fil des années.
ARTESiA: Apixaban vs Aspirin Bleeding Risk with Dr D Siegal
Saison 2 · Épisode 28
mercredi 18 février 2026 • Durée 17:37
Major bleeding remains the principal complication of oral anticoagulation. In patients with device-detected subclinical atrial fibrillation, the decision to anticoagulate requires careful balancing of stroke prevention against bleeding risk.
In this episode of CLOT Conversations, Dr. Deborah Siegal discusses a prespecified subanalysis of the ARTESiA randomized clinical trial, recently published in JAMA Cardiology. ARTESiA demonstrated a 37% reduction in stroke and systemic embolism with apixaban compared to aspirin — but at the cost of increased major bleeding.
This subanalysis goes deeper, examining the site, severity, and clinical course of bleeding events. Most bleeding was gastrointestinal and non-critical. Rates of intracranial and fatal bleeding were low and similar between treatment arms. The majority of events were not clinical emergencies, and many were defined by hemoglobin decline rather than catastrophic presentation.
We explore what these findings mean for individualized risk assessment, the importance of modifiable bleeding risk factors such as NSAID use, and how physicians and patients can approach shared decision-making in subclinical AF.
Abstract (subscription required for full paper):
Siegal DM, Sticherling C, Healey JS, McIntyre WF, Christensen LS, Parkash R, Vanassche T, Conen D, Gold M, Granger CB, Nielsen JC. Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. JAMA cardiology. 2025 Dec;10(12):1305-14.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal
Saison 2 · Épisode 27
mardi 16 décembre 2025 • Durée 21:56
Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps.
In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venous thromboembolism.
The conversation examines bleeding and thrombotic outcomes, mortality, and trough anti-Xa levels, including insights into bioaccumulation and twice-daily versus once-daily dosing. The guests also address study limitations, dose capping in patients with very high body weight, and how WAVe fits into current practice amid increasing DOAC use.
This episode provides practical, evidence-informed guidance for clinicians navigating anticoagulation decisions in obese patients with cancer.
To access the full publication: https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.70127
Please consider supporting Thrombosis Canada by donating today or consider a monthly donation starting at $10: ThrombosisCanada.ca/donate
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
The COBRRA Study: Shifting Paradigms in Acute VTE Treatment
Saison 2 · Épisode 18
vendredi 27 juin 2025 • Durée 04:34
In this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing information, indicating that most acute VTE patients might benefit from apixaban over rivaroxaban, although patient-specific factors and preferences will still play a role in decision-making.
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Breakthrough in DVT Diagnosis: Age-Adjusted D-Dimer Cutoff
Saison 2 · Épisode 17
vendredi 27 juin 2025 • Durée 06:17
In this episode of CLOT Conversations, Dr. Gregoire Le Gal, University of Ottawa, in an interview with Dr Vicky Mai, shares insights from his groundbreaking study on age-adjusted D-dimer cutoffs for diagnosing deep vein thrombosis (DVT). Previously validated for pulmonary embolism (PE), this new approach significantly improves DVT diagnostics. By adjusting D-dimer thresholds based on patient age, the study found a safe and reliable method to rule out DVT without reliance on additional imaging. Though results showed a smaller incremental increase in negative D-dimer results compared to PE, the safety of the approach was confirmed. This research simplifies DVT diagnostics, making it easier for clinicians, especially in emergency settings.
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
COPD-PE Diagnosis & Recurrent VTE with Dr Vicky Mai
Saison 2 · Épisode 16
vendredi 27 juin 2025 • Durée 07:53
In this podcast episode, we explore groundbreaking research presented at the ISTH 2025 in Washington. Dr. Vicky May, Institut Universitaire de Cardiologie et Pneumologie de Québec, shares insights into a new diagnostic algorithm for pulmonary embolism (PE) in patients with chronic obstructive pulmonary disease (COPD). Her work focuses on identifying specific predictors, integrating these with established testing methods, and addressing challenges in the validation process. The discussion also highlights a study on recurrent venous thromboembolism (VTE), emphasizing symptom patterns and recurrence likelihood. These findings aim to refine clinical diagnostics, offering physicians refined tools for better patient management in thrombosis-related conditions.
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Oral anticoagulant drug considerations in Cancer: Dr Tzu-Fei Wang
Saison 2 · Épisode 15
vendredi 27 juin 2025 • Durée 10:38
In this episode of Clot Conversations, Dr. Tzu-Fei Wang, Ottawa, shares a summary of her presentations at the 2025 ISTH meeting on recent studies on drug interactions in prostate cancer therapy and the use of anticoagulants. Dr Wang also highlights the significance of the WAVe study in assessing dalteparin use without the traditional dose cap in patients over 90 kg. These findings offer reassurance to clinicians prescribing anticoagulation therapy, minimizing previous concerns. The discussion provides optimism for improved cancer care protocols, showcasing safer, more effective anticoagulation practices for patients..
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Insights from Patient Experiences with VTE - Dr Stephanie Young
Saison 2 · Épisode 14
vendredi 27 juin 2025 • Durée 10:58
In this episode of Clot Conversations, hosts Jamil Abdulrehman, and Maha Othman interview Dr Stephanie Young from Memorial University in St John's, Newfoundland, at the 2025 ISTH meeting about her presentations on the complexities of patient experiences with Venous Thromboembolism (VTE). Dr Young shares findings from a qualitative study that highlight the uncertainties and emotional impacts patients face along their care journey. Key themes include the need for clearer care pathways, better access to specialized services, and greater involvement in decision-making. The discussion emphasizes integrating patient insights into clinical guidelines to enhance VTE care, aiming for a more patient-centered approach that accounts for both physical and psychological needs.
Dr Young also references the Thrombosis Canada patient resources that can be found here: https://thrombosiscanada.ca/patients_and_caregivers
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Breakthroughs in Thrombosis - research insights
Saison 2 · Épisode 12
jeudi 26 juin 2025 • Durée 11:18
In the latest episode of 'Clot Conversations,' host David Airdrie and guest Dr. Vinai Bhagirath, alongside a talented group of researchers, delve into groundbreaking thrombosis research presented at ISTH 2025. Highlights include Amulya Bhagirath's work on a computerized decision support system for anticoagulation, Dr. Alejandro Godoy's international study on LMWH bridging in patients with mechanical heart valves, Tegvir Grewal's work on perioperative anticoagulation of mechanical aortic valve patients for GI endoscopy and Julia Sharobim's work on transcatheter aortic valve replacement. These studies underline the importance of innovative approaches in thrombosis management, emphasizing Canada's role in driving global research. With promising new insights and collaborations across the globe, this episode showcases the exciting future of thrombosis research.
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Unlocking IVF Success - Dr Elvira Grandone
Saison 2 · Épisode 11
jeudi 26 juin 2025 • Durée 10:21
CLOT Conversations hosts Dr Maha Othman and Dr Jameel Abdulrehman interview Prof Elvira Grandone about two of her presentations at the 2025 ISTH conference in Washington, DC. The first is a discussion about the results of the FIRST Registry that reviews the efficacy of antithrombotic drugs in pregnancy (session OC 05.1).
The second is a discussion of the Pregnancy-Associated Thrombosis Hemorrhage and Anemia (PATH) project. The study aims to examine awareness, current practices and barriers to early identification of anemia and its management in pregnancy. All healthcare professionals involved in the diagnosis and management of anemia in pregnancy. For more information and to participate go to https://REDCap.link/ISTH-PATH
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Reduced-Dose Apixaban for Cancer-Associated Thrombosis: A New Standard?
Saison 2 · Épisode 10
jeudi 24 avril 2025 • Durée 15:36
In this episode of CLOT Conversations, we sit down with Dr. Marc Carrier to explore a groundbreaking study published in the New England Journal of Medicine on reduced-dose apixaban for cancer-associated venous thromboembolism (VTE). Dr. Carrier breaks down the study’s findings, which suggest that a lower dose of apixaban after six months of treatment is just as effective in preventing clot recurrence — and significantly safer in terms of bleeding risk. Tune in for expert insights on how this data could shift clinical practice and improve outcomes for patients living with cancer.
Reference:
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, Sanchez O, Grange C, Monreal M, López-Núñez JJ, Otero-Candelera R. Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2025 Mar 29.
https://thrombosiscanada.ca
Take a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Podcasts Similaires Basées sur le Contenu
